19 April 2022 | News
Ocugen COVAXIN has commercialisation rights for all of North America
Image credit: Shutterstock
Biotech company Ocugen and Bharat Biotech have entered into an amendment to their co-development, supply and commercialisation agreement to expand Ocugen’s exclusive territory to include the commercialisation of COVAXIN in Mexico. This gives Ocugen COVAXIN commercialisation rights for all of North America.
“After meeting with Mexico’s Secretary of Foreign Affairs, Marcelo Ebrard, in Delhi, we are encouraged by the role COVAXINTM can play in Mexico’s continuing efforts to defeat the COVID-19 pandemic. COVAXIN is currently under review by COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios) for emergency use among children between 2 and 18 years of age, and Ocugen is prepared to collaborate with the public health community to help their efforts," said Dr Shankar Musunuri, Chairman of the Board, CEO and Co-founder of Ocugen.
“We are delighted to announce our partnership with Ocugen for Mexico, along with the US and Canada,” said Dr Krishna Ella, CMD, Bharat Biotech.
The license extension between Ocugen and Bharat Biotech for commercialisation in Mexico includes the same profit share structure as in the US.